SecBot SecBot
Biotech Drug Report Generated Aug 21, 2026

Vanrafia

NVS·NOVARTIS AG
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA, Apr 2025). Locally tracked clinical data shows a completed Phase 2 atrasentan study in IgA nephropathy (N
Time to market
Already on the market, FDA approval catalyst recorded 2025-04-02.
Why 3/10
Vanrafia's defining binary already passed, FDA approval recorded 2025-04-02, and no new PDUFA/pivotal readout for it is scheduled in the next ~12 months (no upcoming FDA catalysts for NVS in local data), so per the rubric an approved, commercializing product that is a small part of a ~$285B portfolio scores 3, not higher.
Actionable Insight NEUTRAL

Watch quarterly 6-Ks for Vanrafia's first full-year sales trajectory and any label-expansion or new atrasentan readouts (the Phase 2 crossover study completed Oct 2025, so a publication/next-trial update could come). But treat Vanrafia as immaterial to NVS's share price, the stock trades on the broader portfolio (Kisqali/Pluvicto growth, Entresto generic erosion, pipeline catalysts), not on this single niche product.

Price Chart

Loading chart...

Executive Summary

Vanrafia (atrasentan) is Novartis's oral endothelin-A receptor antagonist for IgA nephropathy, approved by the FDA on April 2, 2025; the local stock-price history shows a modest +2.42% one-day move around that approval. A June 2026 FDA safety-labeling action added a boxed embryo-fetal toxicity warning (contraindicated in pregnancy, contraception required). Vanrafia is one of 30+ products listed in Novartis's Q2 2026 earnings report and is not among the company's headline growth drivers, so for investors it is a minor, already-approved product inside a ~$285B-cap diversified pharma.

How It Works

Atrasentan (Vanrafia) is an endothelin-A receptor antagonist: it blocks the action of endothelin-1, a signaling protein that constricts blood vessels and promotes inflammation and scarring in the kidney. In IgA nephropathy (a disease where antibody deposits damage the kidneys' filters), this reduces protein leaking into the urine and helps slow loss of kidney function. It is taken by mouth.

Trial Status

A randomized, double-blind, placebo-controlled Phase 2 crossover study of atrasentan in IgA nephropathy (NCT05834738) is COMPLETED: started Jul 2023, primary completion Jun 2025, completion Oct 2025, enrollment 54, with results available per the ClinicalTrials.gov record. The FDA approval catalyst for Vanrafia is dated 2025-04-02, and a June 2026 FDA safety-labeling action added an embryo-fetal toxicity boxed warning.

The Two-Sided Case

▲ Bull Case4
Already FDA-approved (approval catalyst dated 2025-04-02 for NVS), no approval risk remains; the stock actually rose +2.42% the day after the approval record (price 106.37 -> 108.94).
Atrasentan is a clinically validated molecule in IgA nephropathy: the local ClinicalTrials.gov record shows a completed, results-bearing Phase 2 randomized crossover study (NCT05834738, n=54) sponsored by Novartis Pharmaceuticals.
Vanrafia is named in Novartis's Q2 2026 earnings 6-K (net sales $14.4B), meaning it is being commercialized with a mega-cap company's infrastructure and reach.
The drug won a first-in-class FDA approval for a kidney disease with few approved options, and Novartis continues to study atrasentan (Phase 2 record updated Jul 2026).
▼ Bear Case4
A June 2026 FDA safety-labeling action imposed a boxed embryo-fetal toxicity warning: Vanrafia is contraindicated in pregnancy and requires pregnancy exclusion plus contraception (and 2 weeks after stopping), a real hurdle for a kidney disease that disproportionately affects younger patients and women of childbearing age.
Vanrafia is a small part of the thesis: it does not appear among the Q2 2026 growth drivers Novartis highlighted (Kisqali +43%, Kesimpta +32%, Scemblix +89%, Pluvicto +43%, Leqvio +59% cc), and its approval catalyst was followed by a -6.15% five-day move.
No new dated binary catalyst for Vanrafia is scheduled in the next ~12 months, so there is no obvious near-term event to re-rate the stock on this drug.
Portfolio-level caution: NVS analyst consensus is 'hold' (mean price target $157.15 vs $156.24 spot, implied upside ~2.5%), Goldman Sachs downgraded to Sell with a $118 target in Sep 2025, and the 60-session weighted short-volume ratio ran at 0.436 (bearish threshold >0.30) per SecBot's bull/bear checklist.

Upcoming Catalysts

  • No FDA catalysts for Vanrafia scheduled in the next 90 days (local data)
  • Quarterly earnings 6-Ks (next: Q3 2026) disclosing Vanrafia sales ramp
  • Potential publication/presentation of completed atrasentan Phase 2 data (NCT05834738, completed Oct 2025) or a next-phase program update

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 sec.gov